International Experts Commend Riyadh’s Lifestyle Transformation Projects
5.5.2019 15:08:00 EEST | Business Wire | Press release
A panel of prominent International experts from various academic and professional fields convened yesterday to discuss Riyadh’s USD23 billion investment in the recently announced 4 Grand Projects that will transform the city and improve the wellbeing of millions of citizens in the capital city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190505005026/en/
Group picture of the international experts attending Riyadh’s Lifestyle Transformation Forum (Photo: AETOSWire)
The Subject Matter Expert (SME) Forum took place at the Exhibition Centre King Fahad Library Plaza on 1st and 2nd May 2019. Discussion centered on a number of topics, including sustainable urban development, conservation, socio-economic well-being, art and culture, and the facilitation of a healthy lifestyle for all citizens.
The 4 Wellbeing Projects will greatly improve Saudis’ way of life by providing a greener, healthier environment and by encouraging participation in cultural and sporting life, in line with the Kingdom’s Vision 2030. These four projects are part of a massive development plan for the capital Riyadh, highlighting the Kingdom's leadership in sustainable urbanization and environmental management.
The Projects are: King Salman Park – one of the world’s largest urban parks with a land area of 13 km2, roughly four times that of Central Park in New York. The park, in addition to its large green spaces, will include a national theatre, opera house and art academy, and will host entertainment, environmental and cultural events. Green Riyadh – an urban greening project that will reduce CO2 levels and cool the city by up to 2°C. Green Riyadh will see 7.5 million trees planted in gardens, parks, mosques, schools and around the capital’s governmental and health sectors. Riyadh Art – a citywide gallery that will include 1,000 works of art and interactive installations, placed in residential areas, public parks, transport facilities and on Riyadh’s roads. Sports Boulevard – the first of its kind in the region, will feature 135 km of multi-purpose track for walking, running, cycling and horse riding.
“What I’ve seen over these two days is very much at the cutting edge and redefines what a city could be. What Riyadh is doing here I haven’t seen anywhere else in the world – where the planning is so integrated and well thought through, and innovative thinking is so evident. Riyadh is setting the standard. I commend these 4 Grand Projects,” John Rossant, Chairman & Founder, New Cities Foundation.
“Every one of these Wellbeing Projects is quite extraordinary. Riyadh will be transformed in ways that you and I can’t fully understand. They will transform this city not just in its infrastructure and facilities, but will transform health, culture and the very way citizens live their lives,” said Dr. David Griggs, Professor, Sustainable Development Institute, Monash University.
“The scale of these city projects is really impressive. Planting a few trees is nice. Maybe planting a couple of blocks is worthy. But it’s only when you get to the scale of 7.5 million trees and 9% green coverage of the city that you can actually change the climate and cool the city down,” John Englander, Oceanographer & Author, commenting on the 7.5 million trees that will be planted as part of the Riyadh Green Project.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190505005026/en/
Contact information
Riyadh Development Authority
Riyadh, Kingdom of Saudi Arabia
Arch.
Khalid Al-Hazani, Director, Architectural Projects Program & Public
Affairs
+966544777772, hazzani@ada.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
